78,413 results match your criteria Lung Cancer Oat Cell Small Cell


Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer.

Cancer Med 2020 Jun 3. Epub 2020 Jun 3.

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.

Aims: High expression of the RNA-binding motif protein 3 (RBM3) correlates with improved prognosis in several major types of cancer. The aim of the present study was to examine the prognostic value of RBM3 protein and mRNA expression in non-small cell lung cancer (NSCLC).

Methods And Results: Immunohistochemical expression of RBM3 was evaluated in surgically treated NSCLC from two independent patient populations (n = 213 and n = 306). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3149DOI Listing

Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.

Oncologist 2020 Jun 3. Epub 2020 Jun 3.

Florida Hospital Cancer Institute, Orlando, Florida, USA.

Background: Little is known about real-world treatment and outcomes of patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC).

Materials And Methods: This retrospective study of the Flatiron Health EHR-derived deidentified database included patients with a lung cancer diagnosis and confirmed advanced NSCLC who received ALK tyrosine kinase inhibitor (TKI) therapy (January 1, 2011, to June 30, 2018). Patient characteristics and treatment patterns were characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2020-0011DOI Listing

ɤ-glutamyl hydroxymethyl rhodamine green fluorescence as a prognostic indicator for lung cancer.

Gen Thorac Cardiovasc Surg 2020 Jun 2. Epub 2020 Jun 2.

Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo, 113-8655, Japan.

Objective: ɤ-glutamyltranspeptidase is an enzyme expressed in various malignancies including lung cancer. It rapidly activates non-fluorescent ɤ-glutamyl hydroxymethyl rhodamine green to highly fluorescent hydroxymethyl rhodamine green. The resultant tumor fluorescence is therefore an indicator of cellular ɤ-glutamyltranspeptidase activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11748-020-01395-2DOI Listing

Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry.

Virchows Arch 2020 Jun 2. Epub 2020 Jun 2.

Department of Pathology, Amsterdam University Medical Center, De Boelelaan, 1117, Amsterdam, The Netherlands.

DLL3 might become a predictive immunohistochemical marker in small cell carcinoma of the lung (SCLC). We investigated the influence of pre-analytical handling of samples on the performance of DLL3 immunohistochemistry (IHC) using DLL3 SP347 ready to use assay (Ventana). DLL3 positive cell lines were subjected to different experimental conditions mimicking the pre-analytical variation in daily clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-020-02848-yDOI Listing

A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L).

Cancer 2020 Jun 2. Epub 2020 Jun 2.

Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Background: A randomized phase 3 study was performed to investigate the efficacy and safety of maintenance therapy with S-1 after induction therapy with carboplatin plus S-1 in patients with advanced squamous non-small cell lung cancer (NSCLC).

Methods: Chemotherapy-naive patients with advanced or relapsed squamous NSCLC were treated with carboplatin (area under the curve of 5 on day 1 every 3 weeks) plus S-1 (40 mg/m twice per day on days 1-14 every 3 weeks) as induction therapy. Patients who did not progress after 4 cycles of induction therapy were randomized to receive either S-1 plus best supportive care (BSC) or BSC alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32987DOI Listing

miR-135a inhibits malignant proliferation and diffusion of non-small cell lung cancer cells by down-regulating ROCK1 protein.

Biosci Rep 2020 Jun 2. Epub 2020 Jun 2.

China-Japan Union Hospital of Jilin University, Changchun, China.

Objective: To seek the clinical significance and regulatory mechanism of miR-135a and Rho-associated protein kinase 1 (ROCK1) in non-small cell lung cancer (NSCLC).

Methods: NSCLC cells were purchased, and miR-135a-mimics, miR-135a-inhibitor, miR-NC, si-ROCK1 and Sh-ROCK1 were transfected into NSCLC cells HCC827 and NCI-H524. qRT-PCR and Western Blot were used to detect the expression of miR-135a, ROCK1, Bax, Caspase3, Bcl-2, N-cadherin, vimentin, E-cadherin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BSR20201276DOI Listing

[The Efficacy of Amrubicin Therapy as a Second Line Treatment in Patients with Small Cell Carcinoma of the Prostate : A Case Report].

Hinyokika Kiyo 2020 Apr;66(4):121-125

The Department of Urology, Gifu University Graduate School of Medicine.

A 68-year-old man was diagnosed with prostate cancer (initial serum prostate specific antigen [PSA] 389 ng/ml, stage cT4N1M1c, Gleason score 5+4), and androgen deprivation therapy was initiated. Despite the low serum PSA level, he developed postrenal acute kidney failure 4 years later, with progression of prostate cancer and liver and lung metastases. Serum levels of neuron-specific enolase and pro-gastrinreleasing peptide (tumor markers) were elevated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_66_4_121DOI Listing

Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.

Endocrinol Diabetes Metab Case Rep 2020 Apr 29;2020. Epub 2020 Apr 29.

Department of Diabetes and Endocrinology, Kanto Central Hospital of the Mutual Aid Association of Public School Teachers, Setagaya-ku, Tokyo, Japan.

Summary: A 72-year-old man with no history of diabetes was referred to our department due to hyperglycemia during pembrolizumab treatment for non-small-cell lung carcinoma. His blood glucose level was 209 mg/dL, but he was not in a state of ketosis or ketoacidosis. Serum C-peptide levels persisted at first, but gradually decreased, and 18 days later, he was admitted to our hospital with diabetic ketoacidosis (DKA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EDM-19-0152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219158PMC

Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report.

Oxf Med Case Reports 2020 Apr 23;2020(4):omaa026. Epub 2020 May 23.

Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, Japan.

The transformation of adenocarcinoma to small cell lung cancer has been reported as acquisition of resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. We here report a patient who presented histologically confirmed transformation of adenocarcinoma to small cell lung cancer after treatment with immune checkpoint inhibitor. A 65-year-old man was treated with pembrolizumab as first-line therapy and achieved temporarily a stable disease with progression after six cycles of this agent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/omcr/omaa026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243716PMC

A Novel Benzofuran Derivative Moracin N Induces Autophagy and Apoptosis Through ROS Generation in Lung Cancer.

Front Pharmacol 2020 12;11:391. Epub 2020 May 12.

College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, China.

Introduction: The leaves of is a traditional Chinese medicine widely applied in lung diseases. Moracin N (MAN), a secondary metabolite extracted form the leaves of L, is a potent anticancer agent. But its molecular mechanism remains unveiled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2020.00391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235196PMC

Long-term outcome comparison for standard fractionation (>59 Gy) versus hyperfractionated (>45 Gy) radiotherapy plus concurrent chemotherapy for limited-stage small-cell lung cancer.

Rep Pract Oncol Radiother 2020 Jul-Aug;25(4):489-493. Epub 2020 Apr 27.

Department of Radiation Oncology, University of Iowa, Iowa City, Iowa, US.

Background: Concurrent chemoradiotherapy (CCRT) is commonly employed in limited-stage small-cell lung cancer (LS-SCLC); however, the optimal radiotherapy regimen is still unknown. This 3-institution analysis compares long-term disease control and survival outcomes for once- (QD) versus twice-daily (BID) radiotherapy at contemporary doses.

Methods And Materials: Data were collected for LS-SCLC patients treated with platinum-based CCRT and planned RT doses of >5940 cGy at >180 cGy QD or >4500 cGy at 150 cGy BID. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rpor.2020.03.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251533PMC

Identification of the Active Compounds and Significant Pathways of Artemisia Annua in the Treatment of Non-Small Cell Lung Carcinoma based on Network Pharmacology.

Med Sci Monit 2020 May 31;26:e923624. Epub 2020 May 31.

College of Acupuncture and Massage, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China (mainland).

BACKGROUND Artemisia annua exerts powerful effects in non-small cell lung carcinoma (NSCLC). Some studies have shown that Artemisia annua possesses the characteristics of new therapeutic drugs for NSCLC patients. However, the underlying molecular mechanism of Artemisia annua anti-NSCLC is not yet fully elucidated because Artemisia annua contains hundreds of ingredients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.923624DOI Listing

LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression.

Mol Cancer 2020 May 30;19(1):98. Epub 2020 May 30.

Clinical Experimental Center, Jiangmen Key Laboratory of Clinical Biobanks and Translational Research, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, 529030, China.

Background: Anti-angiogenic therapy represents a promising strategy for non-small-cell lung cancer (NSCLC) but its application in lung squamous cell carcinoma (SQC) is limited due to the high-risk adverse effects. Accumulating evidence indicates that long noncoding RNAs (lncRNAs) mediate in tumor progression by participating in the regulation of VEGF in NSCLC, which might guide the development of new antiangiogenic strategies.

Methods: Differential lncRNA expression in SQC was analyzed in AE-meta and TCGA datasets, and further confirmed in lung cancer tissues and adjacent normal tissues with RT-qPCR and in-situ hybridization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-020-01217-2DOI Listing

Naphthalenones and naphthols isolated from the Saussurea laniceps endophytic fungus Didymella glomerate X223.

Chem Biodivers 2020 May 30. Epub 2020 May 30.

Sun Yat-Sen University, School of Marine Sciences, high education mega center sysu, China, 511400, Guangzhou, CHINA.

One new naphthalenone, didymelol A (1), and three new naphthols, didymelol B-D (5-7), together with three known naphthalenones, (3S,4R)-3,4,6,8-tetrahydroxy-3,4-dihydronaphthalen-1(2H)-one (2), (S)-4,6,8-trihydroxy-3,4-dihydronaphthalen-1(2H)-one (3), (S)-4,8-dihydroxy-3,4-dihydronaphthalen-1(2H)-one (4), were isolated from the Saussurea laniceps endophytic fungus Didymella glomerate X223. The structures of the isolates were elucidated based on extensive spectroscopic data analysis. The absolute configuration of didymelol A (1) was established through single-crystal X-ray diffraction data and didymelols B-D (5-7) were identified through comparisons of experimental and calculated ECD spectra. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbdv.202000315DOI Listing

Clinical implementation of circulating tumour DNA testing for T790M for detection of treatment resistance in non-small cell lung cancer.

J Clin Pathol 2020 May 29. Epub 2020 May 29.

Division of Clinical Laboratory Genetics, University Health Network, Toronto, Ontario, Canada

Aims: Epidermal growth factor receptor () T790M mutations can be detected in the circulating tumour DNA from plasma of patients with non-small cell lung cancer (NSCLC) to triage patients for osimertinib eligibility and monitor patients longitudinally for development of T790M-mediated resistance.

Methods: Using droplet digital PCR (ddPCR), we examined the T790M status of 343 sequential patients with NSCLC and correlated mutational status with demographic and clinical features. Where available, serial T790M blood test results were assessed to identify clinical triggers and timing of repeat testing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2020-206668DOI Listing

Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.

Cancers (Basel) 2020 May 27;12(6). Epub 2020 May 27.

Nuclear Medicine, Humanitas Clinical and Research Hospital-IRCCS, 20089 Rozzano (MI), Italy.

We investigated the role of soluble PD-L1 (sPD-L1) in non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI) and analyzed its association with clinical outcomes and metabolic parameters by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT). Between July 2017 and May 2019, we enrolled 20 candidate patients of ICI therapy who had serum frozen samples and 18F-FDG PET/CT available, both at baseline and at the first response evaluation. This analysis is embedded into a larger prospective study (NCT03563482). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061373DOI Listing

Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.

Thorac Cancer 2020 May 29. Epub 2020 May 29.

University of Virginia / Riverside, Radiosurgery Center, Newport News, Virginia, USA.

Background: This study reports the outcomes of a single institutional experience treating non-small cell lung cancer (NSCLC) involving the pulmonary hilum with low-dose stereotactic body radiation therapy (SBRT). The authors also present a series of repeat hilar SBRT.

Methods: Inclusion criteria required treatment with SBRT for NSCLC involving regional lymph nodes of the: (i) hilum, (ii) mediastinum, (iii) aortopulmonary window (station 5), or (iv) mainstem bronchus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13501DOI Listing

Prognostic role of extracellular vesicles in squamous cell carcinoma of the lung.

Thorac Cancer 2020 May 29. Epub 2020 May 29.

Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon, South Korea.

Background: Research on diagnosing recurrent non-small cell lung cancer (NSCLC) and applying target gene treatment using exosomes in a less invasive way is very important. Recently, however, it has been argued that exosomes do not contain double-stranded DNA (dsDNA) or histones. In this study, we describe the expression of extracellular vesicle (EV) markers in specimens from squamous cell carcinoma (SCC) of the lung and analyze their relationship with the prognosis of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13492DOI Listing

Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.

ACS Nano 2020 Jun 2. Epub 2020 Jun 2.

Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North Carolina 27695, United States.

CpG oligodeoxynucleotides are potent toll-like receptor (TLR) 9 agonists and have shown promise as anticancer agents in preclinical studies and clinical trials. Binding of CpG to TLR9 initiates a cascade of innate and adaptive immune responses, beginning with activation of dendritic cells and resulting in a range of secondary effects that include the secretion of pro-inflammatory cytokines, activation of natural killer cells, and expansion of T cell populations. Recent literature suggests that local delivery of CpG in tumors results in superior antitumor effects as compared to systemic delivery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsnano.0c02207DOI Listing

Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience.

Radiol Oncol 2020 May 28;54(2):209-220. Epub 2020 May 28.

1st Faculty of Medicine of Charles University in Prague, Prague Czech Republic.

Background Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-world setting in Central European countries to define areas for improvements. Patients and methods This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/raon-2020-0026DOI Listing

[Small-cell lung cancer: management and novelties].

Rev Med Suisse 2020 May;16(695):1079-1085

Service d'oncologie médicale, Département d'oncologie, CHUV, 1011 Lausanne.

Small cell lung cancer is a recalcitrant malignancy with 5-year survival rates of less than 20%. In the majority of cases, patients have metastatic disease at diagnosis despite the new screening method by low-dose CT-scan. The high throughput sequencing has deepened our understanding of its biology. Read More

View Article

Download full-text PDF

Source

Combined Coronary Artery Bypass Grafting, Aortic, and Lung Carcinoma Surgery.

Thorac Cardiovasc Surg Rep 2020 Jan 22;9(1):e21-e23. Epub 2020 May 22.

Department of Cardiovascular Surgery, Robert Bosch Hospital, Stuttgart, Germany.

 Patients presenting with several cardiothoracic conditions that need to be addressed surgically require individual decision making as evidence remains inconclusive and combined surgical procedures carry an elevated perioperative risk.  We present the case and management of a 73-year-old male with myocardial infarction due to three-vessel disease and left main stem stenosis, calcified aortic aneurysm, and right-sided non-small cell lung carcinoma.  High-risk combined surgery should be indicated with scrutiny after individual consideration by an experienced heart team. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0040-1710321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244333PMC
January 2020

Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.

Nat Med 2020 May 27. Epub 2020 May 27.

Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.

Remarkable progress in molecular analyses has improved our understanding of the evolution of cancer cells toward immune escape. However, the spatial configurations of immune and stromal cells, which may shed light on the evolution of immune escape across tumor geographical locations, remain unaddressed. We integrated multiregion exome and RNA-sequencing (RNA-seq) data with spatial histology mapped by deep learning in 100 patients with non-small cell lung cancer from the TRACERx cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-020-0900-xDOI Listing

Association between Adult Height and Risk of Lung Cancer Incidence among Japanese Men: The Miyagi Cohort Study.

Tohoku J Exp Med 2020 05;251(1):51-59

Division of Epidemiology, Department of Health Informatics and Public Health, Tohoku University School of Public Health, Graduate School of Medicine.

It is already known that adult height is a factor associated with an increased risk of colon cancer and postmenopausal breast cancer, pancreatic cancer, premenopausal breast cancer, and ovarian cancer. However, the association between adult height and lung cancer incidence remains unclear. The purpose of the present study was to examine the association between adult height and the risk of lung cancer incidence in the Japanese population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1620/tjem.251.51DOI Listing

3,3',5,5'-tetramethoxybiphenyl-4,4'diol induces cell cycle arrest in G2/M phase and apoptosis in human non-small cell lung cancer A549 cells.

Chem Biol Interact 2020 May 24:109133. Epub 2020 May 24.

Laboratory of Immunoparasitology of Neglected Diseases and Cancer, State University of Londrina, PR, Brazil.

Lung cancer is one of the leading causes of cancer-related death worldwide. It has aggressive manifestation, high ability to promote metastasis and late diagnosis. In the present study, we investigated the cytotoxic effect of 3,3',5,5'-tetramethoxybiphenyl-4,4'diol (TMBP), against the A549 human non-small cell lung carcinoma lineage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbi.2020.109133DOI Listing

Current status and future perspectives of liquid biopsy in non-small cell lung cancer.

J Pathol Transl Med 2020 May 15;54(3):204-212. Epub 2020 Apr 15.

Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blood. Because the technique is minimally invasive, liquid biopsies are the future in cancer management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4132/jptm.2020.02.27DOI Listing

A tetrahedral DNA nanostructure-decorated electrochemical platform for simple and ultrasensitive EGFR genotyping of plasma ctDNA.

Analyst 2020 May 27. Epub 2020 May 27.

Precision Medicine Center, Beilun People's Hospital, Zhejiang University School of Medicine First Affiliated Hospital Beilun Branch, Ningbo, Zhejiang 315806, P. R. China.

Genotyping of the epidermal growth factor receptor (EGFR) mutation status is of great importance in the screening of appropriate patients with advanced non-small cell lung carcinoma (NSCLC) to receive superior tyrosine kinase inhibitor (TKIs) therapy. Yet conventional assays are generally costly with a relatively long turnaround time for obtaining results, which can lead to a bottleneck for immediately starting TKI therapy in late-staged patients. In this study, we propose an on-site electrochemical platform for sensitive simultaneous genotyping of the two major EGFR mutations (19del and L858R) through plasma ctDNA based on tetrahedral DNA nanostructure decorated screen-printed electrodes (SPE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/d0an00591fDOI Listing

Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.

BMC Cancer 2020 May 26;20(1):474. Epub 2020 May 26.

Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Background: Chemotherapeutics can stimulate immune antitumor response by inducing immunogenic cell death (ICD), which is activated by Damage-Associated Molecular Patterns (DAMPs) like the exposure of calreticulin (CRT) on the cell surface, the release of ATP and the secretion of High Mobility Group Box 1 (HMGB1).

Methods: Here, we investigated the levels of ICD-associated DAMPs induced by chemotherapeutics commonly used in the clinical practice of non-small cell lung cancer (NSCLC) and the association of these DAMPs with apoptosis and autophagy. A549 human lung adenocarcinoma cells were treated with clinically relevant doses of cisplatin, carboplatin, etoposide, paclitaxel and gemcitabine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-06964-5DOI Listing

Miliary lung metastases from ROS1-rearranged lung adenocarcinoma: A case report.

Mol Clin Oncol 2020 Jul 4;13(1):80-82. Epub 2020 May 4.

Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa 236-0051, Japan.

Miliary lung metastases are a rare form of metastasis of non-small-cell lung carcinoma. Miliary lung metastases commonly develop in lung adenocarcinoma with epidermal growth factor receptor mutation. In the present study, we present a case of miliary lung metastases from lung adenocarcinoma with ROS1 rearrangement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2020.2040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241238PMC

Prognostic Value of Functional Assessment of Cancer Therapy-General (FACT-G) in Advanced Non-Small-Cell Lung Cancer Treated with Korean Medicine.

Evid Based Complement Alternat Med 2020 20;2020:2845401. Epub 2020 Jan 20.

Department of Clinical Oncology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.

Objectives: The impact of health-related quality of life (HRQoL) on survival has been investigated in patients with various cancers. Here, we evaluated the prognostic value of HRQoL using the Functional Assessment of Cancer Therapy-General (FACT-G) in advanced non-small-cell lung cancer (NSCLC) patients treated with Korean medicine.

Methods: A retrospective review of medical records and FACT-G scores of patients with advanced NSCLC who received treatment with Korean medicine was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/2845401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212313PMC
January 2020

Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene.

Life Sci 2020 May 23;255:117816. Epub 2020 May 23.

Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming 650118, China; Kunming Medical University, Kunming 650100, China. Electronic address:

Non-small cell lung cancer (NSCLC) with RAS -mutant gene has been the most difficult obstacle to overcome. Over 25% of muted lung adenocarcinomas have RAS mutation. The prognosis of NSCLC patients with RAS-mutant genes is always poor because there is no effective drug to suppress RAS-mutant genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lfs.2020.117816DOI Listing

Single nucleotide polymorphisms within the Wnt pathway predict the risk of bone metastasis in patients with non-small cell lung cancer.

Aging (Albany NY) 2020 May 26;12. Epub 2020 May 26.

Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China.

The Wingless-type (Wnt) signaling pathway plays an important role in the development and progression of cancer. This study aimed to evaluate the relationship between single nucleotide polymorphisms (SNPs) in the Wnt pathway and the risk of bone metastasis in patients with non-small cell lung cancer (NSCLC). We collected 500 blood samples from patients with NSCLC and genotyped eight SNPs from four core genes (WNT2, AXIN1, CTNNB1 and APC) present within the WNT pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/aging.103207DOI Listing

Independent Validation of Tumor Budding Activity and Cell Nest Size as Determinants of Patient Outcome in Squamous Cell Carcinoma of the Uterine Cervix.

Am J Surg Pathol 2020 May 22. Epub 2020 May 22.

Department of Pathology, University of California San Diego, La Jolla, CA.

A novel 3-tiered grading system that combines tumor budding activity and cell nest size has been found to be highly prognostic in squamous cell carcinomas (SCCs) of various sites, including lung, oral cavity, larynx, hypopharynx, and esophagus. A similar grading system has recently been proposed for SCC of the uterine cervix. In this study, we appraise this grading system in an institutional cohort of cervical SCC to assess its prognostic value in an independent dataset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001472DOI Listing

Rhombencephalitis associated with isolated Zic4-antibodies in Paraneoplastic cerebellar degeneration: a case report.

BMC Neurol 2020 May 25;20(1):208. Epub 2020 May 25.

Department of Neurology, University Hospital of Gießen and Marburg, Marburg, Germany.

Background: Cerebellar degeneration as a consequence of a malignancy is a rare condition most commonly related to the presence of anti-Yo, anti-Hu, and anti-Tr/DNER antibodies. In recent years, several reports have indicated Zinc-finger protein 4 (Zic4) antibodies being associated with paraneoplastic cerebellar degeneration (PCD) in patients with small cell lung carcinoma. However, the prevalence and the significance of Zic4-antibodies may be underestimated due to their co-occurrence with more frequent antibodies such as anti-Hu. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12883-020-01788-zDOI Listing

[Exploration of the treatment model for patients with advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease based on real-world data].

Zhonghua Jie He He Hu Xi Za Zhi 2020 May;43(5):450-454

Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120,China.

To explore whether combining treatment of chronic obstructive pulmonary disease (COPD) with anti-tumor therapy is better than that of tumor treatment alone in advanced non-small cell lung cancer (NSCLC) patients with COPD in the real world. The clinical data of 101 patients with advanced NSCLC complicated with COPD from January 1, 2015, to December 31, 2017, in the First Affiliated Hospital of Guangzhou Medical University were analyzed retrospectively, including 99 males and two females, aged from 52 to 84 years[average (67±8) years]. Among the patients, 90 (89. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112147-20200304-00241DOI Listing

Molecular Diagnostics in Non-Small Cell Lung Carcinoma.

Authors:
Lynette M Sholl

Semin Respir Crit Care Med 2020 Jun 25;41(3):386-399. Epub 2020 May 25.

Department of Pathology, Harvard Medical School, Boston, Massachusetts.

Current clinical practice guidelines recognize and as essential molecular biomarkers, and a host of other genetic alterations as emerging biomarkers for non-small cell lung carcinoma patients. The available approaches to detecting relevant alterations in these genes are diverse and often complementary. Laboratories have increasingly migrated away from a "single-gene test" approach, embracing assays that incorporate panels of genes capable of detecting a diverse set of alterations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-3399564DOI Listing

Circular RNA hsa_circ_0085131 is involved in cisplatin-resistance of non-small cell lung cancer cells by regulating autophagy.

Authors:
Rui Kong

Cell Biol Int 2020 May 25. Epub 2020 May 25.

Department of Oncology, the Third Affiliated Hospital of Medical University of Chongqing, Chongqing, 401120, China.

Non-small cell lung carcinoma (NSCLC) continues to top the list of cancer mortalities worldwide. The role of circular RNAs (circRNAs) in tumorigenesis has been increasingly appreciated, although it is relatively unexplored in NSCLC. Herein, we reported on the role of hsa_circ_0085131 in NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbin.11401DOI Listing

Resected case of stage IV pleomorphic carcinoma of the lung with long-term survival.

Surg Case Rep 2020 May 24;6(1):106. Epub 2020 May 24.

Department of Thoracic Surgery, Iwakuni Clinical Center, 1-1-1 Atago-machi, Iwakuni-shi, Yamaguchi, 740-8510, Japan.

Background: No established treatments for pulmonary pleomorphic carcinoma exist because of its rarity, and the prognosis is poorer than that of other non-small cell lung cancers.

Case Report: We present a case of stage IV pleomorphic carcinoma; the patient was a 66-year-old male. He was referred to our hospital because of a right adrenal hemorrhage and a lung tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-020-00868-zDOI Listing

Novel visualized quantitative epigenetic imprinted gene biomarkers diagnose the malignancy of ten cancer types.

Clin Epigenetics 2020 May 24;12(1):71. Epub 2020 May 24.

Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.

Background: Epigenetic alterations are involved in most cancers, but its application in cancer diagnosis is still limited. More practical and intuitive methods to detect the aberrant expressions from clinical samples using highly sensitive biomarkers are needed. In this study, we developed a novel approach in identifying, visualizing, and quantifying the biallelic and multiallelic expressions of an imprinted gene panel associated with cancer status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13148-020-00861-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245932PMC

Targeted drug delivery systems: synthesis and in-vitro bioactivity and apoptosis studies of gemcitabine-carbon dots conjugates.

Biomed Mater 2020 May 22. Epub 2020 May 22.

Institute of Marine Biotechnology, Universiti Malaysia Terengganu, Kuala Terengganu, Terengganu, MALAYSIA.

Gemcitabine is used to treat various cancers like breast, pancreatic, non-small lung carcinoma, ovarian, bladder and cervical cancers. Gemcitabine (GEM), however, has the problems of non-selectivity. Water-soluble, fluorescent and mono-dispersed carbon dots (CDs) were fabricated using sucrose by ultrasonic method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1748-605X/ab95e1DOI Listing

[Left atrial invasion for small cell lung carcinoma].

Medicina (B Aires) 2020 ;80(3):303

Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
January 2020

Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 cases.

Ann Diagn Pathol 2020 Apr 20;46:151522. Epub 2020 Apr 20.

Department of Pathology, Marie Lannelongue Hospital, 133 avenue de la Résistance, 92350 Le Plessis Robinson, France.

Beta-catenin, encoded by the CTNNB1 gene, plays an important role in cell proliferation. Mutations of CTNNB1 are oncogenic in several tumor types and are often associated with a nuclear abnormal expression. However, such mutations have only rarely been reported in non-small cell lung carcinomas and their clinical signification is not well described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2020.151522DOI Listing

Inhibition of miR-22 enhanced the efficacy of icotinib plus pemetrexed in a rat model of non-small cell lung cancer.

Iran J Basic Med Sci 2020 Mar;23(3):329-336

Department of Thoracic Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.

Objectives: To investigate the role of miR-22 in the efficacy of combined icotinib (BPI-2009H) and pemetrexed (LY-231514) on tumor growth and apoptosis in rats with non-small cell lung cancer (NSCLC).

Materials And Methods: Rats were injected with HCC827 cells, which were transfected with anti-miR-22, followed by the treatment of BPI-2009H and/or LY-231514. MTT assay was used to detect the inhibition rate of HCC827 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22038/IJBMS.2019.39291.9320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229502PMC

Alpha-1 Antitrypsin Induces Epithelial-to-Mesenchymal Transition, Endothelial-to-Mesenchymal Transition, and Drug Resistance in Lung Cancer Cells.

Onco Targets Ther 2020 4;13:3751-3763. Epub 2020 May 4.

Clinical Laboratory, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610041, People's Republic of China.

Purpose: Alpha-1 antitrypsin (A1AT) is a secreted protein that plays an important role in various diseases. However, the role of A1AT in non-small cell lung cancer is obscure.

Materials And Methods: A1AT expression in non-small cell lung cancer was analyzed using quantitative reverse transcription PCR, Western blotting (WB), immunohistochemistry (IHC), and ELISA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S242579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210034PMC

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).

Cancer Discov 2020 May 21. Epub 2020 May 21.

Perlmutter Cancer Center at NYU Langone Medical Center, New York, New York.

This single-arm, phase I dose-escalation trial (NCT02983045) evaluated bempeg-a-ldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus nivolumab in 38 patients with selected immunotherapy-naïve advanced solid tumors (melanoma, renal cell carcinoma, and non-small cell lung cancer). Three dose-limiting toxicities were reported in 2 of 17 patients during dose escalation [hypotension ( = 1), hyperglycemia ( = 1), metabolic acidosis ( = 1)]. The most common treatment-related adverse events (TRAE) were flu-like symptoms (86. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1510DOI Listing

SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.

Lung Cancer 2020 May 12;145:126-131. Epub 2020 May 12.

AbbVie Inc., South San Francisco, CA, USA.

Objectives: This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma.

Materials And Methods: Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study.

Results: Thirty-five enrolled patients received ≥1 dose of SC-002. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.04.017DOI Listing

Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues.

PLoS One 2020 21;15(5):e0233422. Epub 2020 May 21.

Division of Molecular and Experimental Surgery, Department of Surgery, University Medical Center Erlangen, Friedrich-Alexander University of Erlangen-Nuremberg, Translational Research Center, Erlangen, Germany.

SPARCL1 is a matricellular protein with anti-adhesive, anti-proliferative and anti-tumorigenic functions and is frequently downregulated in tumors such as colorectal carcinoma or non-small cell lung cancer. Studies have identified SPARCL1 as an angiocrine tumor suppressor secreted by tumor vessel endothelial cells, thereby exerting inhibitory activity on angiogenesis and tumor growth, in colorectal carcinoma. It is unknown whether SPARCL1 may exert these homeostatic functions in all organs and in other species. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233422PLOS

Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.

Adv Ther 2020 May 20. Epub 2020 May 20.

S.C. Cardiologia, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Napoli, Italy.

Introduction: Cardiovascular toxicity of immunotherapy represents an underreported but potentially fatal side effect. A relatively high incidence of pericardial disease has been noticed in patients with non-small cell lung cancer (NSCLC).

Methods: We retrospectively analyzed a population of patients with advanced NSCLC receiving immune checkpoint inhibitors (ICIs) looking for the presence of pericardial effusion at baseline or during treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-020-01386-yDOI Listing
May 2020
2.438 Impact Factor

Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma.

Wien Klin Wochenschr 2020 May 20. Epub 2020 May 20.

Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Background: Immune checkpoint inhibitors have become a valuable tool in the therapeutic strategy against metastasized non-small cell lung cancer (NSCLC) as they represent an effective and safe treatment option for many patients; however, the treatment response and side effects of this class of drugs can considerably differ compared to classical chemotherapeutics. The aim of this study was to highlight specific radiological pulmonary findings of NSCLC patients treated with immune checkpoint inhibitors.

Methods And Results: Medical records and images of prospectively collected data from 70 patients with advanced NSCLC, treated with immune checkpoint inhibitors, were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-020-01667-0DOI Listing

Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume.

Radiat Oncol 2020 May 19;15(1):114. Epub 2020 May 19.

Department of Radiation Oncology, Stanford University School of Medicine and Stanford Cancer Institute, 875 Blake Wilbur Dr MC 5847, Stanford, CA, 94305, USA.

Background: We evaluated whether pre- and mid-treatment metabolic tumor volume (MTV) predicts per lesion local recurrence (LR) in patients treated with definitive radiation therapy (RT, dose≥60 Gy) for locally advanced non-small cell lung cancer (NSCLC).

Methods: We retrospectively reviewed records of patients with stage III NSCLC treated from 2006 to 2018 with pre- and mid-RT PET-CT. We measured the MTV of treated lesions on the pre-RT (MTV) and mid-RT (MTV) PET-CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13014-020-01546-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238662PMC